PSMA ligands in prostate cancer – Probe optimization and theranostic applications

Susanne Lütje; Roger Slavik; Wolfgang Fendler; Ken Herrmann; Matthias Eiber

doi:10.1016/j.ymeth.2017.06.026

PSMA ligands in prostate cancer – Probe optimization and theranostic applications

Susanne Lütje, Roger Slavik, Wolfgang Fendler, Ken Herrmann, Matthias Eiber

Research output: Contribution to journal › Review article › peer-review

47 Scopus citations

Abstract

Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as ⁶⁸Ga or ¹⁸F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with ¹³¹I or ¹⁷⁷Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.

Original language	English
Pages (from-to)	42-50
Number of pages	9
Journal	Methods
Volume	130
DOIs	https://doi.org/10.1016/j.ymeth.2017.06.026
State	Published - 1 Nov 2017
Externally published	Yes

Keywords

Imaging
PSMA
Prostate cancer
Theranostics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ymeth.2017.06.026

Cite this

@article{3121816eefbf4157965e151582e7535f,

title = "PSMA ligands in prostate cancer – Probe optimization and theranostic applications",

abstract = "Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as 68Ga or 18F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with 131I or 177Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.",

keywords = "Imaging, PSMA, Prostate cancer, Theranostics",

author = "Susanne L{\"u}tje and Roger Slavik and Wolfgang Fendler and Ken Herrmann and Matthias Eiber",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = nov,

day = "1",

doi = "10.1016/j.ymeth.2017.06.026",

language = "English",

volume = "130",

pages = "42--50",

journal = "Methods",

issn = "1046-2023",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - PSMA ligands in prostate cancer – Probe optimization and theranostic applications

AU - Lütje, Susanne

AU - Slavik, Roger

AU - Fendler, Wolfgang

AU - Herrmann, Ken

AU - Eiber, Matthias

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as 68Ga or 18F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with 131I or 177Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.

AB - Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as 68Ga or 18F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with 131I or 177Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.

KW - Imaging

KW - PSMA

KW - Prostate cancer

KW - Theranostics

UR - https://www.scopus.com/pages/publications/85021796444

U2 - 10.1016/j.ymeth.2017.06.026

DO - 10.1016/j.ymeth.2017.06.026

M3 - Review article

C2 - 28666778

AN - SCOPUS:85021796444

SN - 1046-2023

VL - 130

SP - 42

EP - 50

JO - Methods

JF - Methods

ER -

PSMA ligands in prostate cancer – Probe optimization and theranostic applications

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this